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ABSTRACT 
  
Cancer cells can be viewed as such cells, which have disrupted/aberrant 
signaling pathways for maintaining cellular homoeostasis. Identifying such 
altered signaling mechanisms can help us target these pathways in a better way. 
GDF-2 (Growth and differentiation factor – 2) or BMP9 (Bone morphogenetic 
protein – 9), a multifunctional cytokine, is a member of the Bone Morphogenetic 
Protein subfamily, under TGFβ superfamily, with roles distinct from BMP2/4/7. 
While GDF-2 is known to be one of the most potent ectopic inducers of bone and 
cartilage formation, it rose to significance with the identification of its receptor 
ALK1 in endothelial cells. TGFβ’s role in cancer progression could be described 
as both agonistic and antagonistic. It maintains tissue homeostasis and prevents 
incipient tumors from progressing down the path to malignancy. But cancer cells 
have the capacity to avoid the suppressive influence of TGFβ pathway. 
Pathological forms of TGFβ signaling promote tumor growth and invasion, 
evasion of immune surveillance and cancer cell metastasis. Apart from the C-
terminal phosphorylation of smad2/3 by TGFβ, it can also phosphorylate the 
linker region. We find that GDF-2 can regulate smad phosphorylation by 
phosphorylating smad1/5 at the C-terminus to regulate cell survival [1-5]. 
Interestingly, GDF2 can also mediate linker phosphorylation of smad2 and not 
smad1 in a subset of epithelial cancer and non-cancerous cells. My Studies  
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indicate that GDF-2 mediated linker smad2 phosphorylation can antagonize 
TGFβ signaling implicating that the balance in the level of growth factors is an 
important factor in mediating downstream signaling pathways.
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CHAPTER 1 
INTRODUCTION 
 
1.1 IMPORTANCE OF GDF-2 
 
TGFβ superfamily members have various roles in tumorigenesis. They 
promote cancer in its advanced stage as well as inhibit it in its early stages [6]. 
BMPs comprise an extensive group of conserved and related growth factors, of 
which approximately 20 have been identified so far. BMPs were first identified in 
the extract of bones and were known for their ability to be involved in direct 
ectopic bone formation [7]. Subsequently, apart from being involved in bone 
formation, BMPs were found to be involved in many developmental processes 
like embryonic patterning and early skeletal formation. BMPs also regulate tooth, 
hair, kidney, muscle, skin, and hematopoietic and neuronal development and 
also maintain the iron metabolism and vascular homeostasis in vivo [7]. BMPs 
are divided into 4 subgroups according to the similarity of their amino acid 
sequences and functions. The BMP-2/4 subgroup includes BMP-2, BMP-4 and 
the Drosophila dpp, functioning in the embryonic development. The BMP-7 
subgroup is composed of BMP-5, 6, 7, 8 and the Drosophil gbb. The third is 
GDF-5 subgroup, including GDF-5, 6 and 7. These three subgroups are
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important for keeping up normal tissue functions. BMP 9 and BMP 10 are the 
member of a fourth subgroup whose functions are now being discovered [8]. 
BMPs act through two different type II and type I serine/threonine kinase 
receptors, which are required for downstream signal transduction. The 
serine/threonine kinase domains of type II receptors are constitutively active, and 
phosphorylate Gly-Ser (GS) domains in the type I receptors upon ligand binding, 
leading to the activation of type I receptor kinases. BMPs bind to three different 
type II receptors, i.e. BMP type II receptor (BMPR II), activin type II receptor 
(ActR II) and activin type IIB receptors (ActR IIB). Regarding type I receptors, 
BMPs bind to three different type I receptors, called activin receptor like kinase 
(ALK) 2, ALK3 and ALK6 [9]. 
1.2 OVERVIEW OF THE SIGNALING PATHWAY 	
The gdf-2 gene encodes BMP-9, also known as GDF-2. The role of GDF-2 
in vascularization and angiogenesis has revealed roles in suppressing 
angiogenesis and promoting proliferation in endothelial cells [1, 2, 10, 11]. There 
is little information on the effects of GDF-2 in epithelial cells. The significance of 
GDF-2’s role in epithelial cells comes from the facts that it is predominantly 
expressed in liver, although it’s expression has also been detected in skin and 
heart as well. It also acts as a differentiation factor in the central nervous system 
[12] and it promotes proliferation of hepatocytes [3, 4, 13]. GDF-2 is also shown 
to be a suppressor of breast cancer in vivo [5]. GDF-2 signaling in endothelial 
cells is initiated when it binds to the heteromeric type I/type II receptors. Two 
distinct type I receptor serine threonine kinases have been shown to bind GDF-2: 
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ALK1 in endothelial cells [1, 14] and ALK2 in other cell types [1, 4, 15] and also 
ALK3 and ALK6, in the absence of ALK1 and low ALK2. There are three distinct 
type II receptors, which bind to GDF-2: BMPR II, ActRII and ActRII B [1, 15]. But 
the binding of GDF-2 to type I and type II receptors varies in different cell types. 
Once the ligand binds the receptors, they are activated which in turn activates 
the receptor regulated smads (R-SMADs) smad1, smad5 and smad8, which in 
turn forms a complex with the co-smad smad4. This whole complex gets trans 
located into the nucleus and along with other transcription factors, promotes 
target gene expression and regulation [16].       
 
Figure 1.1 Overview of the BMP signaling pathway; Int. J. Mol. 
Sci. 2014, 15(11), 20656-20667 	
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1.3 STRUCTURAL AND FUNCTIONAL PROPERTIES OF GDF-2 
 
Like all other TGFβ ligands, GDF-2 is synthesized as a large pre-pro-
protein. Once dimerization occurs, the pro domain is cleaved from the active 
GDF-2; however, it still remains attached to GDF-2 through non-covalent 
interactions [14]. Expression of GDF-2 in different organs has been studied and it 
has been found that hepatocytes are by far the best producers of GDF-2 and 
moreover, it has been observed that similarly to TGFβ, GDF-2 circulates in active 
and inactive forms [17]. However, unlike TGFβ, the pro-domain of GDF-2 does 
not bind to ECM, meaning that GDF-2 is not inhibited to enter the circulation, 
resulting in a much higher concentration of GDF-2 in the serum [17]. The 
estimated level of GDF-2 in the blood is around 2-20 ng/ml, which is much higher 
than the EC50 for ALK1 activation. Indeed, aortic endothelial cells showed 
endogenously phosphorylated smad1/5/8 proteins, presumably due to sustained 
activation by circulating GDF-2 molecules [17]. 
The functional properties of GDF-2 are not very well understood. In fact, 
GDF-2 knockout mice did not show defects in angiogenesis [18], even though 
multiple studies have identified GDF-2 as an important factor for vasculature 
maintenance [1]. Knockout of the GDF-2 receptor, ALK1, is embryonically lethal, 
while haploinsufficiency in ALK1 leads to a genetic disorder called hereditary 
hemorrhagic telangiectasia type 2 (HHT2), which is characterized by abnormal 
vessel formation [19]. 
	 5 
Early studies have described GDF-2 as a vascular quiescence factor [20]. 
Subsequent studies have shown that GDF-2 inhibits VEGF-induced 
angiogenesis and endothelial cell proliferation [1]. Recent studies, however, have 
reported the ability of GDF-2 to mediate proliferation of multiple types of 
endothelial cells both in vitro and in vivo, most likely by up regulating VEGF 
receptors and Angiopoetin-1/Tie2 expression [2]. These findings are not 
surprising, as ALK1 signaling up regulates ID1 and ID3 protein expression [21], 
which are strong promoters of angiogenesis [22]. Interestingly, the soluble form 
of ALK1 was recently reported to inhibit tumor growth in mouse models [23]. As 
with other TGFβ superfamily ligands, the functional role of GDF-2 remains 
controversial and is likely extremely cell and context dependent. 
Apart from angiogenesis, GDF-2 is also known to have many other effects 
in vitro and in vivo. As most other BMPs, GDF-2 can function as an osteogenic 
and chondrogenic factor [24]. Additionally, GDF-2 can also regulate metabolism, 
by inhibiting glucose production and up regulating important enzymes of lipid 
homeostasis [25]. 
The most intriguing part of GDF-2 signaling is the contradiction of 
outcomes in its studies. In breast cancer cells, administering GDF-2 has shown 
to decrease HER-2 protein and transcript levels and reduce the tumor volume in 
nude mice [26]. On the other hand, GDF-2 acts as a pro-proliferating factor 
through the ALK2/SMAD1/SMAD4 pathway in epithelial ovarian cancer cells [15]. 
This pro-tumorigenic or anti-tumorigenic role of GDF-2 is still a subject of 
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investigation and the gap, whether GDF-2 is a critical factor in cancer 
progression remains unexplored
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CHAPTER 2 
 
COMPONENTS OF THE SIGNALING PATHWAY 
 
2.1 SMAD FAMILY 	
 
Figure 2.1 The smad family of proteins; Indian Journal of Cancer, Vol. 48, No. 
3, July-September, 2011, pp. 351-360 
 
Smads are intracellular proteins, which relay signaling from TGFβ ligands 
to the nucleus. There are three types of smads: R-smad (receptor regulated), Co-
smad (common mediator) and I-smad (inhibitory). Smads 1, 2, 3, 5, 8 are R-
smads and can be phosphorylated by type I receptors in the C- terminus. Binding 
of smad proteins to the type I receptors is aided by the presence of smad anchor 
for receptor activation (SARA) protein. Once phosphorylated, smads dissociate
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from the receptors and form heteromeric complexes with smad4 [27]. Upon 
phosphorylation, smad complexes translocate to the nucleus, where they are 
able to interact with transcription factors and be recruited to specific promoter 
elements. Usually, each type I receptor is associated with only a subset of 
smads. Out of ALK 4, 5, 7, all phosphorylate smad2 and smad3, while ALK 1, 2, 
3 and 6 induce smad 1, 5, 8 phosphorylation [28].  
2.2 NON-SMAD PATHWAYS 
2.2.1 P38 PATHWAY 
 
The TGFβ and BMP receptor family not only induces activation of smad 
proteins, but also are also capable of activating other signaling molecules such 
as MAPKs, ERK, p38 and others. Perhaps the most recognized non-SMAD 
pathway initiated by TGFβ superfamily is p38 MAPK pathway. p38 exists at the 
third level of MEK phosphorylation, meaning that there are at least two sequential 
phosphorylation events before p38 can become phosphorylated. It is thought that 
p38 MAPK is activated through MKK3/6 [29]. Further upstream, MKK3/6 is 
activated through a TGFβ kinase (TAK1). Multiple studies have shown that TAK1 
deficient cells are unable to signal through p38 pathway [30, 31]. Interestingly, 
p38 pathway is completely independent from smad signaling, as smad2/3 or 
smad4 deficient cells are prefectly capable of activating these pathways [32]. 
Recent studies have revealed that TGFβ receptors cannot only be 
phosphorylated on their serine/threonine residues, but can also be activated 
through phosphorylation of tyrosine residues [33]. TβRII cytoplasmic domain 
contains three tyrosine residues, which upon phosphorylation can recruit scaffold 
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proteins, which in turn initiate non-SMAD signaling pathways [34].  
 
Figure 2.2 Overview of the MAPK pathway; Can J Ophthalmol. 2009 Aug; 
44(4): 431-6 
 
												 2.2.2 ERK PATHWAY 
 
Several studies have shown that TGFβ can induce ERK activation. 
Interestingly, in some cells ERK phosphorylation occurs rapidly within minutes of 
TGFβ binding, suggesting a direct method of recruitment [35]. In contrast, other 
cells show a delayed response, happening hours after stimulation, implying that 
protein synthesis is required for signaling to occur [36]. As in the case of p38 
signaling, phosphorylation of tyrosine residues on TβRII plays a crucial role in 
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ERK signaling. Moreover, like p38, smad involvement is not needed to induce 
ERK phosphorylation [37]. 
2.2.3 GDF-2 SIGNALING 
 
GDF-2 can also activate non-smad pathways [38]; however, no extensive 
research has been done to elucidate the exact mechanisms of smad-
independent pathways. It is likely that GDF-2 initiates non-smad signaling 
similarly to TGFβ, by phosphorylating tyrosine residues allowing for protein 
docking [38]. Several studies have shown that BMPs, including GDF-2 can 
induce MAPK pathways, through TAK1, leading to p38 MAPK or JNK activation 
[39]. Additionally, BMPs are also shown to induce ERK phosphorylation [39]. 
Interestingly, GDF-2 has also been found to have an inhibiting effect on PI3K/Akt 
pathway, which is activated by TGFβ signaling, implying that ALK1 and ALK5 
pathways could function in opposition to each other [40]. 
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CHAPTER 3 
 
EXPLORING THE LINKER REGION OF SMADS 
 
The R-smads consist of two conserved globular domains, namely the MH1 
and MH2 domains connected by a more divergent linker region [41].  
The MH1 domain binds DNA, whereas the MH2 domain binds the 
membrane receptors for activation, nucleoporins for nuclear translocation, and 
other smads and nuclear factors to form transcriptional complexes [42]. The 
diversity of the linker region, which consists of several serine and threonine 
residues, allows for regulation of R-smads by multiple signaling inputs. The linker 
region of smad1 consists of four MAPK phosphorylation sites (Ser-187, 195, 206 
and 214), whereas smad2/3 consists of four SP/TP sites for proline-directed 
kinases. In response to mitogens, Erk MAPK mediates the phosphorylation of 
these sites in vivo [43, 44]. CDK2 and CDK4 have also been known to mediate 
the phosphorylation of some of the linker residues in smad2/3 in addition to 
residues at the N-terminus of smad2/3 [45]. p38 MAPK and JNK also 
phosphorylate the linker region of smad2/3 and regulate their transcriptional 
activity [46, 47]. The MAPK mediated phosphorylation of the linker region
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generally results in the inhibition of smad1 activity [43, 48] and attenuation of 
nuclear accumulation of smad1 [43]. Similarly, MAPK mediated attenuation of 
smad2 activity has been attributed to smad2 linker phosphorylation [44, 49]. In 
Xenopus embryogenesis, linker phosphorylation of smad1 through MAPK plays 
an important role in inhibiting BMP signaling, which results in neural induction 
[48]. Linker phosphorylation of smad2/3 during Xenopus embryogenesis results 
in cytosolic retention of smad2/3 and inhibition of TGFβ signaling [49].   
 
Figure 3.1 Different phosphorylation sites of the linker region of smad 
proteins; Cell Research (2009) 19:8–20 
 
The TGFβ and BMP pathways are intensely regulated by inputs that 
adjust pathway activity according to contextual status. Antagonists such as 
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fibroblast growth factor (FGF) and epidermal growth factor (EGF) and cell stress 
signals act through MAPKs to cause phosphorylation of a region that links the 
DNA binding and transcriptional domains of the smads [43, 48-50]. Linker 
phosphorylation of smads in the basal state leads to their cytoplasmic retention 
and ubiquitin ligase-driven; proteasomal degradation [51, 52], with an attendant 
decrease in the responsiveness of cells to BMP and TGFβ signals [43, 44, 48, 
49]. Smad linker phosphorylation by antagonists provides a critical 
counterbalance to TGFβ and BMP signaling. This has led to postulates that in the 
canonical pathways C-tail phosphorylation activates smad signaling and linker 
phosphorylation inhibits it [52, 53]. However, this dichotomy is not so tidy. BMP 
induced smad1 linker phosphorylation that has been reported previously [52], 
has revealed unexpected facets of the canonical TGFβ and BMP pathways. 
Unlike linker phosphorylation by antagonistic signals, which is cytoplasmic and 
MAPK mediated, agonist induced linker phosphorylation occurs during or directly 
prior to the assembly of smad proteins into transcriptional complexes and is 
mediated by CDK8 and CDK9 [54].  
MAPK mediated linker phosphorylation appears to have a dual role in 
smad2/3 regulation. Mitogens and hyperactive Ras result in extracellular signal 
regulated kinase (ERK)-mediated phosphorylation of smad3 at Ser 204, 208 and 
Thr 179 and of smad2 at Ser 245/250/255 and Thr 220. Mutation of these sites 
increases the ability of smad3 to activate target genes, suggesting that MAPK 
phosphorylation of smad3 is inhibitory [44, 55]. However, in contrast, ERK 
dependent phosphorylation of smad2 at Thr 8 enhances its transcriptional activity 
	 14 
[56]. Phosphorylation of smad3 by p38 MAPK and ROCK (Ser 204, Ser 208 and 
Ser 213) and c-Jun N-terminal kinase (JNK) (Ser 208 and Ser 213; analogous to 
Ser 250 and Ser 255 in smad2) may enhance smad2/3 transcriptional activity, 
suggesting that smads and the p38/ROCK/JNK signaling pathways might 
cooperate in generating a more robust TGFβ response [46, 47, 57]. A significant 
increase in Ser 208/Ser 213 phosphorylation of smad3 is associated with late 
stage colorectal tumors, suggesting that the linker-phosphorylated smad3 may 
mediate the tumor-promoting role of TGFβ in late tumorigenesis.   
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CHAPTER 4 
 
THESIS OBJECTIVES 
 
4.1 RATIONALE 
 
There are many studies where it has been shown that GDF-2 acts through 
ALK1 in endothelial cells [1, 10, 58]. GDF-2 can also act via ALK2 [15] in other 
cell lines, where ALK1 is absent or present in very low levels. A recent study from 
our lab has shown that GDF-2 can also activate smad1/5 signaling by increasing 
a complex formation between ALK3 and 6 and type II receptor BMPRII 
(unpublished data). As these receptors all induce the smad1/5/8 pathway, it 
would suggest that smad independent signaling pathways are also involved. 
BMPs are also known to regulate a variety of smad independent pathways 
including the p38 and ERK MAPK signaling pathways [9]. Our data suggests that 
GDF-2 is also able to induce smad2 but not smad1 linker phosphorylation, which 
in turn retain smad2 in the cytoplasm and not allow it to go into the nucleus, 
which would further suggest that non smad pathway(s) (p38, ERK) might be 
involved upstream of smad2, since canonical smad pathways usually denote C-
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terminal phosphorylation of smads and that leads to nuclear translocation of 
smads.  
4.2 HYPOTHESIS 
 
GDF-2 phosphorylates the linker region of smad2 and blocks its nuclear 
translocation and it also suppresses TGFβ mediated smad2 signaling. 
4.3 SPECIFIC AIMS 
 
• To test whether GDF-2 mediates canonical smad1/5/8 signaling in 
tumorigenic ovarian epithelial cells 
• To test whether GDF-2 is able to phosphorylate the linker region of smad2 
and prevent its nuclear translocation and whether GDF-2 is able to 
suppress TGFβ mediated smad2 signaling. 
	 17 
CHAPTER 5 
 
MATERIALS AND METHODS 
 
5.1 CELL LINES AND THEIR CULTURE 	
Ovarian tumorigenic cell lines HEY, 4T1, BT 474, SKOV3 and OvCa 429 
were cultured in RPMI supplemented with 10% FBS, L-glutamine and 100U 
penicillin/streptomycin. HMvEC cells were maintained in endothelial cell growth 
medium containing 10% FBS and MCF10A cells were maintained in DMEM/F12 
medium supplemented with 5% horse serum, 20ng/ml EGF, 0.5mg/ml 
hydrocortisone, 100ng/ml cholera toxin, 10µg/ml insulin and 100U Pen/Strep. All 
cells lines were maintained at 37°C in a humidified incubator at 5% CO2. 
5.2 ANTIBODIES, REAGENTS AND PLASMIDS 	
Antibodies phosphosmad1/5 (#9516S), phosphosmad2/3 (#8828S), 
phosphosmad2 (#3104S), smad1 (#6944S), smad2 (#3103S) and p38 MAPK 
(#8690S), GAPDH (#2118S) and fibrillarin (#2639S) were from Cell Signaling 
Technology. Inhibitors SB203580 (#PHZ1253) and U0126 (#PHZ1283) were
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from Invitrogen. GDF-2 and TGFβ were from R&D systems. Constructs 
expressing pE2.1 was a kind gift from Miyazono, K [59].  
5.3 TRANSCRIPTION REPORTER LUCIFERASE ASSAY 	
Cells were grown in a 24 well plate and transfected with pE 2.1 vector 
containing the luciferase gene under 36 bp-pE2.1 element of PAI-1 gene [60-62] 
and the pRL-SV40 vector expressing Renilla luciferase under the control of SV40 
promoter to control for transfection efficiency using Lipofectamine 2000. The cell 
were incubated with GDF-2 (10 ng/ml) and TGFβ (100 pM) for 24 hours, after 6 
hours of serum starvation in SKOV3 and 24 hours of serum starvation in HEY. 
Cells were collected and lysed in 1x passive lysis buffer (Promega) according to 
manufacturer’s instructions. To measure luciferase activity, 20µl of lysate was 
added to 25µl of Luciferase Reporter Assay Reagent (Promega) and 
luminescence was quantitated using a luminometer (Biotek).  
5.4 SUB-CELLULAR FRACTIONATION 	
HEY cells were serum starved (overnight) and treated with the ligands for 
30 minutes when they were 90-100% confluent. Then they were harvested from 
90-100% confluent P10 dish and subjected to sub-cellular fractionation, 
according to the manufacturer’s protocol from the Cell Signaling (#9038S). 
5.5 WESTERN BLOTTING 
 
Protein samples were heated to 90°C for 5 minutes and subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10 or 12.5% 
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acrylamide gels, followed by transfer to nitrocellulose membranes for 1 hour at 
10 volts. Membranes were blocked for 30 minutes in 5% non-fat dried milk in 
Tris-buffered saline, after which they were incubated overnight with primary 
antibody in 5% bovine serum albumin in Tris-buffered saline with 0.1% Tween 
20, followed by 1 hour with fluorescent secondary antibody.  
5.6 IMMUNOFLUORESCENCE AND MICROSCOPY 	
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3% TX-100 
and blocked with 1% BSA in PBS. Primary antibody (1:200) incubation for an 
hour was followed by 30 minutes incubation with Alexa Fluor® 488 (H+L) 
(#A11008 Life Technologies). After washing, cells were stained with 4, 6-
diamidino-2-phenylindole (DAPI; Roche). Imaging was carried out using a Zeiss 
LSM700 confocal microscope. 
 
5.7 STATISTICAL ANALYSIS 	
Statistical analysis was performed by Student’s t-test analysis. 
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CHAPTER 6 
 
RESULTS 	
6.1 GDF-2 activates smad1/5 signaling in both normal and tumorigenic 
epithelial cells 
It has been known that GDF-2 is a ligand for ALK1 in endothelial cells [10], 
but its role in normal and oncogenic epithelial cells that don’t have ALK1 receptor 
is still not clear. To find out whether GDF-2 would also mediate downstream 
signaling pathways in non-tumorigenic and tumorigenic epithelial cell lines, a time 
dependent analysis of smad1/5 phosphorylation was carried out in both 
tumorigenic (BT 474, OvCa 429, HEY and SKOV3) and non-tumorigenic 
(HMvEC and MCF10A) cell lines. Robust smad1/5 signaling was seen as early 
as 5 minutes or 15 minutes after GDF-2 treatment [Figure 6.1]  
Since previous studies have indicated that BMP superfamily members 
(BMP 2/4) can activate the smad2/3 pathways as well [63], I examined smad2/3 
signaling in two of these cell lines. I found out that GDF-2 did not phosphorylate 
smad2/3 and subsequently did not mediate smad2/3 signaling [Figure 6.2].
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Consistent with smad1/5 activation in response to GDF-2 treatment, I 
observed clear nuclear translocation of smad1/5 [Figure 6.3] in 4T1 cells, a 
mouse mammary epithelial model. Therefore, I concluded that GDF-2 exclusively 
mediates smad1/5 phosphorylation and signaling.  
6.2 GDF-2 induces phosphorylation of linker region of smad2 but not    
smad1 and this might be via the MAPK pathway 
It has been previously observed that BMPs induce smad1 linker 
phosphorylation at four different MAPK phosphorylation sites (Ser-187, 195, 206 
and 214) [52]. The MAPK mediated phosphorylation of the linker region generally 
results in the inhibition of smad1 activity [43, 48] and attenuation of the nuclear 
accumulation of smad1 [43]. Similarly, TGFβ induced MAPK mediated 
attenuation of smad2 activity has been attributed to smad2 linker phosphorylation 
[44, 49]. Therefore, to find out whether GDF-2 is also inducing smad1 linker 
phosphorylation, I examined smad1 linker phosphorylation in different 
tumorigenic cell lines [Figure 6.4]. 
Surprisingly, I observed that GDF-2 did not induce smad1 linker 
phosphorylation, although it very clearly induces smad1/5 phosphorylation in 
both tumorigenic and non-tumorigenic cell lines. Historically, it has been known 
that GDF-2 is not able to induce smad2/3 phosphorylation and subsequently, it’s 
signaling [10] and it has always been associated with smad1/5 signaling. But 
since, I did not observe any smad1 linker phosphorylation in any of the cell lines, 
I opted to see if GDF-2 could induce smad2 linker phosphorylation and 
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surprisingly, I observed smad2 linker getting phosphorylated by GDF-2 in a time 
dependent manner [Figure 6.5]. This observation is novel and there are no 
previous reports of smad2 linker region getting phosphorylated by GDF-2. 
Smad1 linker region gets phosphorylated by MAPKs [43, 48, 52] and although I 
could not observe any smad1 linker phosphorylation by GDF-2, I could clearly 
conclude that GDF-2 is phosphorylating the smad2 linker. . 
To find out whether MAPK pathway is involved in this phenomenon, I took 
the help of two inhibitors: U0126 (MEK inhibitor) and SB203580 (p38 MAPK 
inhibitor). It was again surprising to observe that the two inhibitors, individually, 
and in a combinatorial way, were able to suppress smad2 linker phosphorylation 
mediated by GDF-2 [Figure 6.6].  
Thus, I was able to make the conclusion that GDF-2 induces smad2 but 
not smad1 linker phosphorylation in a subset of tumorigenic epithelial cells and it 
might be mediating that via MAPK pathway.  
6.3 GDF-2 mediates the retention of linker-phosphorylated smad2 in the 
cytoplasm and it does not allow the nuclear translocation of C-terminal 
phosphorylated smad2 
 
Linker phosphorylation of smads in the basal state leads to their 
cytoplasmic retention and ubiquitin ligase-driven; proteasomal degradation [51, 
52], with a concomitant decrease in the responsiveness of cells to BMP and 
TGFβ signals [43, 44, 48, 49]. Smad linker phosphorylation by antagonists 
provides a critical counterbalance to TGFβ and BMP signaling. This has led to 
postulates that in the canonical pathways, C-tail phosphorylation activates smad 
	 23 
signaling and linker phosphorylation inhibits it [52, 53]. Also, TGFβ is historically 
known to phosphorylate smad2/3 and mediate it’s signaling [64] and it also 
promotes the nuclear translocation of smad2/3 for target gene regulation. To find 
out whether GDF-2 exhibits the same effects as TGFβ in retaining smad2 in the 
cytoplasm after it’s linker region gets phosphorylated, I did subcellular 
fractionation in HEY cells and separated the cytosolic and nuclear fraction. Then 
the different fractions were blotted for phosphorylated smad2 linker and 
phosphorylated C-terminal of smad2 [Figure 6.7]. I observed that when the linker 
region of smad2 gets phosphorylated, surprisingly almost all of smad2 gets 
retained in the cytoplasm. Thus, it was clearly evident that GDF-2 acts in the 
same manner as TGFβ while phosphorylating the linker region of smad2 and 
then the retention of it in the cytoplasm. The interesting part of this observation is 
that although GDF-2 falls under the TGFβ superfamily, it is not at all similar to 
TGFβ and is expected to act in a manner similar to the other BMPs, since GDF-2 
also induces smad1/5 phosphorylation.  
Therefore, the reason why GDF-2 cannot induce smad2/3 C-terminal 
phosphorylation and mediates it’s nuclear translocation might be due to the fact 
that GDF-2 induces smad2 linker phosphorylation and hence, inhibits it’s 
downstream canonical signaling. 
6.4 GDF-2 might be inhibiting the TGFβ mediated smad2/3 signaling 
pathway and it may be doing it via smad2 linker region phosphorylation. 
The next step of my research was to find out the consequences of the 
smad2 linker phosphorylation by GDF-2. There have been many previous reports 
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of smad linker phosphorylation by TGFβ and BMPs, and all are related to the fact 
that the linker phosphorylation of the smads helps them to get retained in the 
cytoplasm and subsequently attenuates their nuclear accumulation, which in turn 
inhibits BMP or TGFβ signaling [43, 44, 48, 49]. I assumed that there might be 
some biological consequences of smad2 linker phosphorylation by GDF-2 due to 
the known fact that linker phosphorylation disrupts nuclear translocation of smad 
proteins. Since it was a novel observation that GDF-2 is able to phosphorylate 
smad2 and not smad1 linker, I proceeded to study the effects of GDF-2 mediated 
smad2 linker phosphorylation on TGFβ mediated signaling with the luciferase 
reporter assay, as TGFβ is known to be the ligand which phosphorylates 
smad2/3. HEY and SKOV3 cells were transfected with pE2.1-luciferase, a 
luciferase reporter gene under the control of TGFβ responsive PAI-1 based 
promoter and the GDF-2 mediated gene induction with and without TGFβ was 
assayed by measuring luciferase activity [Figure 6.8].          
As evident from the figure above that gene induction by TGFβ is 
approximately 3- fold down in the presence of GDF-2 in HEY, and almost 1.5-fold 
down in SKOV3. This might be due to the fact that GDF-2 is suppressing TGFβ 
mediated signaling via smad2, by phosphorylating the linker region of smad2, 
which subsequently are not being able to translocate into the nucleus, thus 
lowering the target gene expression. 
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Figure 6.1 GDF-2 activates smad1/5 in tumorigenic and non-tumorigenic 
epithelial cells. Western blotting of lysates from (a) BT 474, (b) SKOV3, (c) 
HEY, (d) OvCa 429, (e) MCF10A, (f) HMvEC, treated with GDF-2 (10ng/ml) for 
the indicated times (minutes) and immunoblotted for psmad1/5 and smad1. 
 
	
 
Figure 6.2 GDF-2 does not activate smad2/3 in epithelial cells. Western 
blotting of lysates from (a) OvCa 429, (b) HEY, treated with GDF-2 (10ng/ml) for 
the indicated times (minutes) and immunoblotted for psmad2/3 and smad2.   
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Figure 6.3 SMAD1 translocates into the nucleus. Immunofluorescence images 
of 4T1 cells treated with GDF-2 for 30 minutes, followed by immunostaining for 
smad1  
	
	
Figure 6.4 GDF-2 does not induce smad1 linker phosphorylation in 
tumorigenic epithelial cells. Western blotting of lysates from (a) SKOV3, (b) 
HEY, (c) BT 474, treated with GDF-2 (10ng/ml) for the indicated times (minutes) 
and immunoblotted for psmad1 linker and smad1.  
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Figure 6.5 GDF-2 induces smad2 linker phosphorylation in tumorigenic 
epithelial cells. Western blotting of lysates from (a) HEY, (b) SKOV3, (c) BT 
474, treated with GDF-2 (10ng/ml) for the indicated times (minutes) and 
immunoblotted for psmad2 linker and smad2. 
 		
	
	
Figure 6.6 GDF-2 might be inducing smad2 linker phosphorylation via 
MAPK pathway. Western blotting for psmad2L activation in (a) HEY and (b) 
SKOV3 in the presence and absence U0126 (10µM) and SB203580 (10µM) with 
and without GDF-2 (10ng/ml) as indicated.   
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Figure 6.7 GDF-2 mediated smad2 linker phosphorylation inhibits smad2 to 
translocate into the nucleus. HEY cells were treated with GDF-2 (10ng/ml) and 
fractionated into nuclear and cytoplasmic fractions. Twenty micrograms of protein 
were loaded from each fraction for western blotting and immunoblotted for 
psmad2 linker, psmad2/3 (C-terminal), smad2, GAPDH and fibrillarin. GAPDH 
and fibrillarin is cytoplasmic and nuclear marker, respectively.   
	 29 
	
 
Figure 6.8 GDF-2 is able to suppress TGFβ mediated signaling. (a) HEY and 
(b) SKOV3 cells were transfected with pE2.1-luciferase and treated with GDF-2 
(10ng/ml) and TGFβ (100pM). The cells were then assayed by measuring 
luciferase activity. Data are shown as fold induction (relative to untreated cells). 
Statistical analysis was carried out using the paired t-test, ★★  = P<0.0001.
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CHAPTER 7 
 
DISCUSSION 
 
My study shows for the first time a role of GDF-2 in inducing smad2 linker 
phosphorylation in epithelial cells [Figure 6.5]. It has been historically observed 
that BMPs and GDF-2 are able to induce smad signaling but it is somewhat 
restricted to smad1/5 [Figure 6.1], and BMPs are also shown to induce smad1 
linker phosphorylation but never smad2 or smad3 [1-5]. Therefore, my 
assumption was that GDF-2 would also induce smad1 linker phosphorylation and 
not smad2 linker. But I observed that GDF-2 is inducing smad2 linker 
phosphorylation instead of smad1 linker, which has not been reported before. I 
also noticed that GDF-2 is promoting the retention of smad2 in the cytoplasm via 
the phosphorylation of smad2 linker not allowing for it’s nuclear translocation 
[Figure 6.7]. The novelty in these observations is that GDF-2 is somehow 
mimicing TGFβ and showing the same effects on smad linker phosphorylation. I 
observed that similar to TGFβ’s induction of linker phosphorylation via MAPK 
pathway [43, 44, 48, 49], GDF-2 is also able to activate the MAPK proteins and in
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turn induce the linker phosphorylation of smad2 [Figure 6.6]. Another aspect of 
my study was to look for GDF-2’s ability to suppress TGFβ mediated signaling. 
With the help of luciferase gene reporter assay, I was able to conclude that GDF-
2 is indeed suppressing TGFβ mediated signaling. There are a lot of areas where 
this study can further go. The first of them would be to look for the different 
receptors (type I, II or III), which are responsible for bringing about the 
phosphorylation of linker region of smad2. One of the issues is that epithelial 
cells have very low levels of ALK1, which is known to be the specific receptor for 
GDF-2 in endothelial cells. Although previous studies have shown that GDF-2 
can act via ALK2 [4, 15] or ALK3 (unpublished data from our group), and it’s 
capacity to induce smad signaling is enhanced in the presence of Endoglin (a 
type III receptor) [65, 66], the question remains as to whether these receptors are 
also able to induce the linker phosphorylation in smads. There are different sites 
of phosphorylation in smads where MAPK proteins can phosphorylate. It is not 
known whether the same residues, which are getting phosphorylated by GDF-2, 
are the ones, which are responsible for TGFβ’s suppression, by GDF-2. Site 
directed mutagenesis might be one of the ways to study this particular effect of 
GDF-2 on TGFβ. Linker phosohorylation of smads might be one of the key 
aspects of smad dynamics between the cytoplasm and nucleus. It’s downstream 
biological consequences and relevance like cell proliferation, migration, invasion, 
might be used for therapeutical approaches.
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